secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2023-03-09T23:59:59+00:00
Accession:  0000950170-23-006834
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA places FTX-6058 on clinical hold; Fulcrum reports Q4/FY2022 results
-----------------------------------------------------------------------

- FDA placed full clinical hold on FTX-6058 IND for sickle cell disease; enrollment paused and dosing suspended.
- Phase 1b 12 mg cohort showed up to 10% absolute HbF increase; company working to address FDA concerns.
- Losmapimod Phase 3 REACH trial enrollment on track to complete in second half of 2023.
- Completed $117.3M public offering in January 2023; cash runway extends into mid-2025.
- CMO Santiago Arroyo resigned; Iain Fraser appointed Interim CMO, effective March 9, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000095017023006834/0000950170-23-006834-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000095017023006834/fulc-20230309.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-006834

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer